Name: Latest research reports of Dr. Lal Pathlabs Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Dr. Lal Pathlabs Ltd.
Rating: 3
Author: ICICI Securities Limited

Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Industry: Healthcare Services
| Strong Performer, Getting Expensive

3148.7000 49.60 (1.60%)

NSE Jul 31, 2025 15:06 PM

37.28% Gain from 52W Low

Volume: 242.6K

Dr. Lal Pathlabs Ltd.

24 Oct 2024

3148.70

1.60%

Growth moderates; near term green shoots unlikely

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q2FY25 revenue growth of 9.8% YoY was lower than our expectation, though its better EBITDA margin of 30.7% was a surprise.

Emkay released a Buy report for Dr. Lal Pathlabs Ltd. with a price target of 3100.0 on 20 Jul, 2025.